Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5502-5510

  Chmielewska, Alicja M ^a   Naddeo, Mariarosaria ^a   Capone, Stefania ^a   Ammendola, Virginia ^a   Hu, Ke ^b   Meredith, Luke ^b   Verhoye, Lieven ^c   Rychlowska, Malgorzata ^a   Rappuoli, Rino ^d   Ulmer, Jeffrey B ^e   Colloca, Stefano ^a   Nicosia, Alfredo ^a,f,g   Cortese, Riccardo ^a,h   Leroux Roels, Geert ^c   Balfe, Peter ^b   Bienkowska Szewczyk, Krystyna ^a   Meuleman, Philip ^c   McKeating, Jane A ^b   Folgori, Antonella ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c GHENT UNIVERSITY   (Belgium)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Okairos AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; IMMUNOGLOBULIN G; MIFAMURTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GENOTYPE; GUINEA PIG; HEPATITIS C; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; GENETIC VECTORS; GUINEA PIGS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; POLYSORBATES; RECOMBINANT FUSION PROTEINS; SQUALENE; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84899101186     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03574-13     Document Type: Article

References (51)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010 .03432.x.
2. Lange CM, Zeuzem S. 2013. Perspectives and challenges of interferonfree therapy for chronic hepatitis C. J. Hepatol. 58:583-592. http://dx.doi .org/10.1016/j.jhep.2012.10.019.
3. Shi C, Ploss A. 2013. Hepatitis C virus vaccines in the era of new directacting antivirals. Expert Rev. Gastroenterol. Hepatol. 7:171-185. http://dx .doi.org/10.1586/egh.12.72.
4. Neumann-Haefelin C, Thimme R. 2013. Adaptive immune responses in hepatitis C virus infection. Curr. Top. Microbiol. Immunol. 369:243-262. http://dx.doi.org/10.1007/978-3-642-27340-7_10.
5. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. 2003. Memory CD8+T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197:1645-1655. http://dx.doi.org/10.1084/jem.20030239.
6. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 104:6025-6030. http://dx.doi.org/10.1073 /pnas.0607026104.
7. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 101:10149-10154. http://dx.doi.org/10.1073 /pnas.0403519101.
8. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27. http: //dx.doi.org/10.1038/nm1698.
9. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. 2011. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53:755-762. http://dx.doi.org /10.1002/hep.24171.
10. Ball JL, Tarr WA, McKeating JA. 26 February 2014. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. http: //dx.doi.org/10.1016/j.antiviral.2014.02.013.
11. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. 15 January 2014. Clearance of hepatitis C infection is associated with early appearance of broad neutralizing antibody responses. Hepatology http://dx.doi.org/10.1002/hep.27013.
12. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C, Kansopon J, McFarland J, Tabrizi A, Ching K, B. Moss B, Cummins LB, Houghton M, Muchmore E. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 91:1294-1298. http://dx.doi.org/10.1073 /pnas.91.4.1294.
13. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. 2011. Immunization ofhumanvolunteers with hepatitisCvirus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J. Infect. Dis. 204:811-813. http://dx.doi.org/10.1093/infdis/jir399.
14. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH. 2011. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J. Infect. Dis. 204:1186-1190. http://dx.doi.org/10.1093/infdis/jir511.
15. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M. 2007. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25: 7773-7784. http://dx.doi.org/10.1016/j.vaccine.2007.08.053.
16. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. 2011. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85:596-605. http://dx.doi.org/10 .1128/JVI.01592-10.
17. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P, McKeating JA. 2008. HepatitisCvirus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17-24. http://dx.doi.org/10.1002 /hep.21959.
18. Meredith, LW, Harris HJ, Wilson GK, Fletcher NF, Balfe P, McKeating JA. 2013. Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J. Hepatol. 58:1074-1080. http://dx.doi.org/10 .1016/j.jhep.2013.01.019.
19. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85:3173-3188. http://dx.doi.org/10.1099 /vir.0.80401-0.
20. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313. http://dx.doi.org/10.1128/JVI.77.11.6305-6313.2003.
21. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, Liao HX, Kepler TB, Haynes BF, Ramsburg E. 2008. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26:6108-6118. http://dx.doi.org/10.1016/j.vaccine.2008.09.007.
22. Draper SJ, Heeney JL. 2010. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8:62-73. http://dx.doi.org/10 .1038/nrmicro2240.
23. Tatsis N, Ertl HC. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10:616-629. http://dx.doi.org/10.1016/j.ymthe.2004.07.013.
24. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. 2012. Novel adenovirus-based vaccines induce broad and sustained T cell responses toHCVin man. Sci. Transl. Med. 4:115ra111. http: //dx.doi.org/10.1126/scitranslmed.3003155.
25. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. 2012. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4:115ra112. http://dx.doi.org/10.1126/scitranslmed.3002925.
26. Takahashi K, Iwata K, Matsumoto M, Matsumoto H, Nakao K, Hatahara T, Ohta Y, Kanai K, Maruo H, Baba K, Hijikata M, Mishiro S. 2001. Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited. Hepatol. Res. 20: 161-171. http://dx.doi.org/10.1016/S1386-6346(00)00141-8.
27. Roccasecca R, Folgori A, Ercole BB, Puntoriero G, Lahm A, Zucchelli S, Tafi R, Pezzanera M, Galfre G, Tramontano A, Mondelli MU, Pessi A, Nicosia A, Cortese R, Meola A. 2001. Induction of cross-reactive humoral immune response by immunization with mimotopes of the hypervariable region 1 of the hepatitis C virus. Int. Rev. Immunol. 20:289-300. http://dx.doi.org/10.3109/08830180109043040.
28. Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A. 2006. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80:1688-1699. http://dx.doi.org/10.1128/JVI.80.4 .1688-1699.2006.
29. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu DM, Shiver JW, Volkin DB. 2004. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 93:2458-2475. http://dx.doi.org/10.1002/jps.20157.
30. Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, Simon AJ, Laufer R, La Monica N, Cortese R, Nicosia A. 2000. Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J. Virol. 74:11598-11607. http: //dx.doi.org/10.1128/JVI.74.24.11598-11607.2000.
31. Gottwein JM, Bukh J. 2008. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv.Virus Res. 71:51-133. http://dx.doi.org/10.1016/S0065-3527(08)00002-X.
32. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. 2003. Hepatitis C virus glycoproteins mediate pHdependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A. 100:7271-7276. http://dx.doi.org/10.1073/pnas.0832180100.
33. Cottingham MG, Carroll F, Morris SJ, Turner AV, Vaughan AM, Kapulu MC, Colloca S, Siani L, Gilbert SC, Hill AV. 2012. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol. Bioeng. 109:719-728. http://dx.doi.org/10.1002 /bit.24342.
34. Hillen W, Berens C. 1994. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu. Rev. Microbiol. 48:345-369. http: //dx.doi.org/10.1146/annurev.mi.48.100194.002021.
35. Hillen W, Gatz C, Altschmied L, Schollmeier K, Meier I. 1983. Control of expression of the Tn10-encoded tetracycline resistance genes. Equilibrium and kinetic investigation of the regulatory reactions. J. Mol. Biol. 169:707-721.
36. Dahari H, Feinstone SM, Major ME. 2010. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 139:965-974. http://dx.doi.org/10.1053/j .gastro.2010.05.077.
37. Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince AM, Sung YC. 2005. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42:1429-1436. http://dx.doi.org/10.1002/hep.20934.
38. de Cassan SC, Draper SJ. 2013. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev. Vaccines 12:365-378. http://dx.doi.org/10 .1586/erv.13.11.
39. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW. 2010. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:950-957. http://dx.doi.org/10.1016/j.vaccine.2009.10.145.
40. Matthews DA, Cummings D, Evelegh C, Graham FL, Prevec L. 1999. Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J. Gen. Virol. 80(Part 2):345-353.
41. Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, Mondelli MU, Amoroso P, Cortese R, Nicosia A, Vitelli A, Folgori A. 2004. Multispecific T cell response and negativeHCVRNAtests during acuteHCVinfection are early prognostic factors of spontaneous clearance. Gut 53:1673-1681. http://dx.doi.org/10.1136/gut.2003.037788.
42. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. 2005. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42:104-112. http://dx .doi.org/10.1002/hep.20749.
43. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, Houghton M, Frey SE, Belshe RB. 2010. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 202:862-866. http://dx.doi.org/10.1086/655902.
44. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. 2010. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28:6367-6373. http://dx.doi.org/10.1016/j.vaccine.2010 .06.084.
45. Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset FL, Tangy F, Klatzmann D, Bellier B. 2009. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J. Gene Med. 11:313-325. http://dx.doi.org/10.1002/jgm.1307.
46. Swadling L, Klenerman P, Barnes E. 2013. Ever closer to a prophylactic vaccine for HCV. Expert Opin. Biol. Ther. 13:1109-1124. http://dx.doi .org/10.1517/14712598.2013.791277.
47. Li YP, Kang HN, Babiuk LA, Liu Q. 2006. Elicitation of strong immune responses by aDNAvaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World J. Gastroenterol. 12:7126-7135.
48. Song MK, Lee SW, Suh YS, Lee KJ, Sung YC. 2000. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNAprimed mice. J. Virol. 74:2920-2925. http://dx.doi.org/10.1128/JVI.74.6 .2920-2925.2000.
49. Lin Y, Kwon T, Polo J, Zhu YF, Coates S, Crawford K, Dong C, Wininger M, Hall J, Selby M, Coit D, Medina-Selby A, McCoin C, Ng P, Drane D, Chien D, Han J, Vajdy M, Houghton M. 2008. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J. Virol. 82:7492-7503. http://dx.doi.org/10.1128/JVI.02743-07.
50. Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cattaneo R. 2012. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J. Virol. 86:11558-11566. http://dx.doi.org/10 .1128/JVI.01776-12.
51. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chene I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3:94ra71. http://dx.doi.org/10.1126/scitranslmed.3002330.